New Zealand Pharmaceuticals and Healthcare Report Q1 2016

78 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: New Zealand’s updated Health Strategy draft will see limited improvement to the challenging
business environment for innovative drugmakers. Cost minimisation continues to be a key aspect of the
approach adopted, with the Pharmaceutical Management Agency maintaining its dominant role in curbing
pharmaceutical spending. Nonetheless, there will be opportunities for other segments of the health industry,
such as telecare, which is poised to play a critical role in enabling New Zealand to achieve its objectives.
Headline Expenditure Forecasts
? Pharmaceuticals: NZD1.45bn (USD1.20bn) in 2014 to NZD1.48bn (USD1.04bn) in 2015; 2.0% in local
currency terms and -11.4% in US dollar terms. Forecast unchanged from last quarter.
? Healthcare: NZD22.57bn (USD18.72bn) in 2014 to NZD23.10bn (USD16.17bn) in 2015; 2.4% in local
currency terms and -13.6% in US dollar terms. Forecast in US dollar terms with a slight downward
revision due to currency effects.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2013-2019) 7
SWOT 9
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2011-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019) 20
New Zealand 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019) 22
OTC Medicine Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2013-2019) 26
Table: Pharmaceutical Trade Data And Forecasts (local currency, New Zealand 2013-2019) 26
Industry Risk Reward Index 27
Asia Pacific Risk/Reward Index 27
New Zealand Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Regulatory Development 36
Intellectual Property Issues 36
Pricing & Reimbursement Regime 37
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn) 42
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010 43
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (New Zealand 2009-2014) 47
Table: Healthcare Activity (New Zealand 2009-2014) 48
Table: Healthcare Personnel (New Zealand 2009-2014) 48
Research & Development 49
Clinical Trials 49
Epidemiology 51
Competitive Landscape 55
Research-Based Industry 55
Table: Multinational Market Activity 56
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 57
Company Profile 59
Douglas Pharmaceuticals 59
New Zealand Pharmaceuticals 62
Pfizer New Zealand 65
Demographic Forecast 67
Table: Population Headline Indicators (New Zealand 1990-2025) 68
Table: Key Population Ratios (New Zealand 1990-2025) 68
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025) 69
Table: Population By Age Group (New Zealand 1990-2025) 69
Table: Population By Age Group % (New Zealand 1990-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts (local currency, New Zealand 2013-2019)
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
Table: Healthcare Resources (New Zealand 2009-2014)
Table: Healthcare Activity (New Zealand 2009-2014)
Table: Healthcare Personnel (New Zealand 2009-2014)
Table: Multinational Market Activity
Table: Population Headline Indicators (New Zealand 1990-2025)
Table: Key Population Ratios (New Zealand 1990-2025)
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
Table: Population By Age Group (New Zealand 1990-2025)
Table: Population By Age Group % (New Zealand 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • New Zealand Pharmaceuticals and Healthcare Report Q4 2015BMI View: Over the forecast period New Zealand will continue to present a gradually deteriorating operating environment for drugmakers. Pharmac's limited and oversubscribed budget, will not allow for significant expansion in the volume and value of the pharmaceutical market as prices are held down. However, if ratified the Trans Pacific Partnership would likely place great restraints on Pharmac's ability to do so and see New Zealand's regulators forced to accept higher prices for […]
  • New Zealand Pharmaceuticals and Healthcare Report Q2 2015BMI View: Despite policy initiatives designed to increase the pace of generic penetration, high latent demand for branded pharmaceuticals will continue to be underpinned by New Zealand's ageing and expanding population. However, the conversion of such potential into rewards for multinationals will remain largely dependent upon PHARMAC's budget which, already oversubscribed, is unlikely to receive significant extensions to its annual increase over our forecast period. As such, New […]
  • New Zealand Pharmaceuticals and Healthcare Report Q2 2016BMI View: The free reign that New Zealand's Pharmaceutical Management Agency (PHARMAC) has over pharmaceutical spending will come under pressure. While the agency's stringent approach to listing medicines has helped to curtail drug spending, it has limited access to novel 'first-in-class' medicines. This in turn has created public pressure from both patient groups and politicians that could infringe upon PHARMAC's operations. The Trans-Pacific Partnership will also have ramifications […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Morocco Pharmaceuticals and Healthcare Report Q1 2015BMI View: Our outlook for Morocco's pharmaceutical market remains relatively optimistic over the shortto- long term. Increased access to healthcare in Morocco following the implementation of the final phase of its universal health insurance scheme will drive an increase in pharmaceutical spending. The country's reliance on pharmaceutical imports will provide opportunities for multinational drugmakers, though the inefficient regulatory environment is a risk to operating in […]